Uncovering the spectrum of healthcare resource utilization and costs across moderate to severe asthma: high-cost subgroups and impact of biologics
Results indicate patients receiving GINA 3 treatment can have a high disease burden and may benefit from treatment with a biologic.
Authors
- Jeremiah Hwee (ORCID: https://orcid.org/0000-0002-2623-7706)
- Justin Kwiatek (ORCID: https://orcid.org/0000-0002-1862-0238)
- Victoria S. Benson (ORCID: https://orcid.org/0000-0002-3775-1401)
- Qinggong Fu
- Rafael Alfonso-Cristancho
Institutions
- Providence College (US)
- GlaxoSmithKline (United States) (US)
Publication Details
- Journal
- Journal of Asthma
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/02770903.2024.2441882
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33